Clinical characteristics at HU start
| Characteristic . | Value . |
|---|---|
| Patients, N | 416 |
| Sex, male/female, n (%) | 154/262 (37/63) |
| Median age, y (range) | 66 (18-95) |
| Less than 40 | 24 (6) |
| 40-60 | 119 (28) |
| More than 60 | 273 (66) |
| JAK2 V617F/JAK2* wt, n (%) | 231/148 (61/39) |
| Patients with thrombosis, n (%) | 161 (39) |
| AMI | 32 (20) |
| Stroke/TIA | 77 (48) |
| PAT | 16 (10) |
| VTE | 36 (22) |
| Median time from diagnosis to HU start, mo (range) | 4.9 (0-255) |
| Less than 1 y, n (%) | 258 (62) |
| 1-5 y, n (%) | 108 (26) |
| More than 5 y, n (%) | 50 (12) |
| Patients on aspirin, n (%) | 324 (78) |
| Characteristic . | Value . |
|---|---|
| Patients, N | 416 |
| Sex, male/female, n (%) | 154/262 (37/63) |
| Median age, y (range) | 66 (18-95) |
| Less than 40 | 24 (6) |
| 40-60 | 119 (28) |
| More than 60 | 273 (66) |
| JAK2 V617F/JAK2* wt, n (%) | 231/148 (61/39) |
| Patients with thrombosis, n (%) | 161 (39) |
| AMI | 32 (20) |
| Stroke/TIA | 77 (48) |
| PAT | 16 (10) |
| VTE | 36 (22) |
| Median time from diagnosis to HU start, mo (range) | 4.9 (0-255) |
| Less than 1 y, n (%) | 258 (62) |
| 1-5 y, n (%) | 108 (26) |
| More than 5 y, n (%) | 50 (12) |
| Patients on aspirin, n (%) | 324 (78) |
AMI indicates acute myocardial infarction; TIA, cerebral transient ischemic attack; PAT, peripheral arterial thrombosis; and VTE, venous thromboembolism.
Percentages calculated on 379 JAK2 V617F evaluated patients.